Association Between Prosthetic Knee Effusions and Phosphodiesterase Type-5 Enzyme Inhibitor Use After Total Knee Arthroplasty: A Case Report. Issue 1 (10th January 2023)

• Record Type: Journal Article
• Authors: Anibas, Jakob J.; Brady, Nicholas; Cheppalli, Naga Suresh
• Is Part Of: JBJS case connector. Volume 13:Issue 1(2023)
• Publication Date: 2023-01-10
• Subjects: periprosthetic -- prosthetic -- total knee arthroplasty -- erectile dysfunction -- male -- effusion -- swelling -- aseptic -- osteoarthritis -- PDE5 inhibitor -- sildenafil -- tadalafil; Orthopedic surgery -- Case studies -- Periodicals; Orthopedic surgery -- Periodicals; Orthopedics; Orthopedic Procedures; Orthopedic surgery; Periodicals; Electronic journals; Case studies; Periodicals; 616.7
• DOI: 10.2106/JBJS.CC.22.00622
• Languages: English
• ISSNs: 2160-3251

Abstract

Abstract : Case: Phosphodiesterase type-5 enzyme (PDE5) inhibitors are well tolerated and used to treat erectile dysfunction. We report a case of prosthetic knee effusions associated with PDE5 inhibitor use in a 65-year-old man after total knee arthroplasty (TKA). PDE5 inhibitor treatment was stopped, and the patient had no further episodes of painful effusions. Conclusion: This report describes a previously unknown adverse effect of PDE5 inhibitor use in a prosthetic joint after TKA. We hope to encourage physicians managing patients after joint replacement to be aware of the association between PDE5 inhibitor use and recurrent joint effusions to improve postoperative outcomes.